• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    What Is Drawing Fresh Attention To Tarsus Pharmaceuticals (TARS)?

    Simply Wall St·11/07/2026 02:34:48
    Listen to the news

    Tarsus Pharmaceuticals (TARS) has just posted record third quarter revenue and product sales, raised its full-year revenue guidance, and confirmed Neera Clase as permanent Chief Commercial Officer to lead commercial execution.

    Recent trading tells a mixed story. Tarsus Pharmaceuticals’ share price has fallen 8.35% over the past week and 6.81% over the past month, despite a 5.88% 90 day share price gain and a very large 3 year total shareholder return of about 3x. This reflects strong longer term performance alongside cooling near term enthusiasm.

    Scan how Tarsus Pharmaceuticals compares with other high potential healthcare names by reviewing our curated list of 35 healthcare AI stocks.

    Tarsus Pharmaceuticals has just paired record sales and higher guidance with a sharp pullback in the share price. Does that recent drop offer a cleaner entry now, or does patience make more sense as valuation gets unpacked next?

    Most Popular Narrative: 31% Undervalued

    Tarsus Pharmaceuticals closed at $68.60 while the most followed narrative pegs fair value around $99.50, pointing to a wide valuation gap that hinges on execution against ambitious growth assumptions and margin expansion.

    Accelerated patient and physician adoption of XDEMVY, driven by a robust direct-to-consumer campaign and increased unaided awareness, points to ongoing demand expansion among an estimated 25 million potential U.S. patients, suggesting material runway for future top-line revenue growth.

    Strong demographic tailwinds from an aging population and higher prevalence of chronic conditions such as Demodex blepharitis are expected to enlarge Tarsus' core addressable market, fueling long-term sustainable revenue increases.

    See why 15 investors see Tarsus Pharmaceuticals as 31% undervalued.

    Result: Fair Value of $99.50 (UNDERVALUED)

    Still, the Tarsus Pharmaceuticals story leans heavily on XDEMVY, and any slowdown in uptake or rising SG&A pressure could quickly challenge that undervaluation thesis.

    Find out about the key risks to this Tarsus Pharmaceuticals narrative.

    Next Steps

    If the Tarsus Pharmaceuticals story so far feels split between optimism and caution, move fast and check the underlying figures yourself, weighing both the upside and downside. To see both sides laid out clearly in one place, review the 3 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond Tarsus Pharmaceuticals?

    If Tarsus Pharmaceuticals has sharpened your focus on quality opportunities, do not stop here. Broaden your watchlist and pressure test your next move with fresh ideas.